Cited by 573Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

Open access

Kelly, Karen, Chansky, Kari, Gaspar, Laurie E., Albain, Kathy S., Jett, James, Ung, Yee C., Lau, Derick H.M., Crowley, John J., Gandara, David R.·2008·Journal of Clinical Oncology

DOI 10.1200/jco.2007.14.4824

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Early clinical studies with gefitinib showed promising efficacy and mild toxicity in patients with advanced non-small-cell lung cancer (NSCLC). Thus, gefitinib was an ideal agent to evaluate in a maintenance setting in stage III disease. PATIENTS AND METHODS: Untreated patients with stage III NSCLC, a performance score of 0 to 1, and adequate organ function were eligible. All patients received cisplatin 50 mg/m(2) on days 1 and 8 plus etoposide 50 mg/m(2) on days 1 to 5, every 28 days for two cycles with concurrent thoracic radiation (1.8- to 2-Gy fractions per day; total dose, 61 Gy) followed by three cycles of docetaxel 75 mg/m(2). Patients whose disease did not progress were randomly assigned to gefitinib 250 mg/d or placebo until disease progression, intolerable toxicity, or the end of 5 years. The planned sample size was 672 patients to confer power of 0.89 to detect a 33% increase over the expected median survival time of 21 months (one-sided P = .025, log-rank test). Random assignment was stratified by stage, histology, and measurable versus nonmeasurable disease. RESULTS: Enrollment began in July 2001. An unplanned interim analysis conducted in April 2005 rejected the alternative hypothesis of improved survival at the P = .0015 level for 243 randomly assigned patients. The study closed, and preliminary results were reported. Now, with a median follow-up time of 27 months, median survival time was 23 months for gefitinib (n = 118) and 35 months for placebo (n = 125; two-sided P = .013). The toxic death rate was 2% with gefitinib compared with 0% for placebo. CONCLUSION: In this unselected population, gefitinib did not improve survival. Decreased survival was a result of tumor progression and not gefitinib toxicity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2007.14.4824

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Self-citation
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W. J., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & VARMUS, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,517
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490

Flagged first, then by citations

Show all 31 references

Sorted by citations

Items 301–400 of 573

Induction treatment in patients with stage III non-small cell lung cancer
Palmero, R., Vilariño, N., Navarro-Martín, A., & Nadal, E. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-420 · Cited by 13
Concurrent Chemoradiation Therapy With or Without Nimotuzumab in Locally Advanced Squamous Cell Lung Cancer: A Phase 2 Randomized Trial
Qiu, B., Wang, D., Li, Q., Wu, Y., Guo, S., Jiang, X., Fang, J., Guo, J., Liu, F., Chu, C., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.06.032 · Cited by 11
Non-Small-Cell Lung Cancer Clinicopathologic Features and Survival Outcomes in Asian Pacific Islanders Residing in the United States: A SEER Analysis
Hamid, M. S., Shameem, R., Gafoor, K., George, J., Mina, B. A., & Sullivan, K. M. (2015) · Journal of Cancer Epidemiology · doi:10.1155/2015/269304 · Cited by 11
Combination of radiotherapy and chemotherapy in locally advanced NSCLC
Kępka, L., Sprawka, A., Casas, F., Abdelwahab, S., Agarwal, J. P., & Jeremic, B. M. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.121 · Cited by 11
The Marriage of Growth Factor Inhibitors and Chemotherapy: Bliss or Bust?
Staal, S. P., O’Connell, M. J., & Allegra, C. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.3224 · Cited by 11
Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectives
Adamo, V., Franchina, T., Adamo, B., Denaro, N., Gambadauro, P., Chiofalo, G., Scimone, A., Caristi, N., Russo, A. D., & Giordano, A. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.3.7465 · Cited by 11
ACR Appropriateness Criteria® Nonsurgical Treatment for Non-Small-Cell Lung Cancer: Good Performance Status/Definitive Intent
Gewanter, R. M., Rosenzweig, K. E., Chang, J. Y., Decker, R. H., Dubey, S., Kong, F., Lally, B. E., Langer, C. J., Lee, H. K., & Movsas, B. (2010) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2010.04.001 · Cited by 11
Combined Radio- and Chemotherapy for Non-Small Cell Lung Cancer: Systematic Review of Landmark Studies Based on Acquired Citations
Nieder, C., Pawinski, A., & Andratschke, N. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00176 · Cited by 11
Chemoradiation for Definitive, Preoperative, or Postoperative Therapy of Locally Advanced Non-Small Cell Lung Cancer
Feliciano, J. L., Feigenberg, S. J., & Mehta, M. P. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e318293238d · Cited by 10
Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer
Ito, H., Matsuo, Y., Ohtsu, S., Nishimura, T., Terada, Y., Sakamoto, T., & Mizowaki, T. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01566-z · Cited by 10
A narrative review of toxicity of chemoradiation and immunotherapy for unresectable, locally advanced non-small cell lung cancer
Prasad, R. N., & Williams, T. M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-638 · Cited by 10
Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer
Kim, D. W. N., Nam, T., Choe, K. S., & Choy, H. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.2.74 · Cited by 10
Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions
Chen, H. X., Cleck, J. N., Coelho, R. P., & Dancey, J. E. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.10.002 · Cited by 10
Perspective on treatment for unresectable locally advanced non-small cell lung cancer with oncogene-driven mutation: a narrative review
Jiang, L., Meng, X., Zhao, X., Xing, L., & Yu, J. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-722 · Cited by 10
Does Gefitinib Shorten Lung Cancer Survival? Chaos Redux
Keedy, V. L., Arteaga, C. L., & Johnson, D. H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0374 · Cited by 10
Concurrent Hyperfractionated Radiation Therapy and Chemotherapy in Locally Advanced (Stage III) Non-Small-Cell Lung Cancer: Single Institution Experience With 600 Patients
Jeremic, B. M., Miličić, B., & Milisavljevic, S. S. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.04.016 · Cited by 9
Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
Schütte, W., Gutz, S., Nehls, W., Blum, T. G., Brückl, W. M., Buttmann‐Schweiger, N., Büttner, R., Christopoulos, P., Delis, S., Deppermann, K.-M., et al. (2023) · Pneumologie · doi:10.1055/a-2029-0134 · Cited by 11
Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
Ibrahim, E. M. (2010) · Annals of Thoracic Medicine · doi:10.4103/1817-1737.65047 · Cited by 9
Genomic Biomarkers For Patient Selection And Stratification: The Cancer Paradigm
Moschos, S. A. (2012) · Bioanalysis · doi:10.4155/bio.12.241 · Cited by 9
Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung cancer
Yamaguchi, M., Nakagawa, K., Suzuki, K., Takamochi, K., Ito, H., Okami, J., Aokage, K., Shiono, S., Yoshioka, H., Aoki, T., et al. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa249 · Cited by 9
Targeted therapies for unresectable stage III non-small cell lung cancer
Remón, J., & Hendriks, L. E. L. (2021) · Mediastinum · doi:10.21037/med-21-8 · Cited by 9
A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy
Wu, R., Yu, S., Ye, J., Wang, Y., Zhao, Z., Liu, H., & Song, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.692703 · Cited by 9
The Optimal Chemotherapy for Stage III Non–Small Cell Lung Cancer Patients
Gadgeel, S. M. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0170-3 · Cited by 9
Molecularly Targeted Therapies in Locally Advanced Non–Small-Cell Lung Cancer
Devarakonda, S. H. K., Morgensztern, D., & Govindan, R. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.03.005 · Cited by 9
Fludarabine combined with radiotherapy in patients with locally advanced NSCLC lung carcinoma: a phase I study
Nitsche, M., Christiansen, H., Lederer, K., Griesinger, F., Schmidberger, H., & Pradier, O. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1185-3 · Cited by 9
Three-Arm Randomized Trial of Sodium Alginate for Preventing Radiation-Induced Esophagitis in Locally Advanced Non–Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy: The OLCSG1401 Study Protocol
Ninomiya, K., Ichihara, E., Hotta, K., Sone, N., Murakami, T., Harada, D., Oze, I., Kubo, T., Tanaka, H., Kuyama, S., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.08.001 · Cited by 9
Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer
Zhang, Y., Lin, Q., Xu, T., Deng, W., Yu, J., Liao, Z. X., & Yue, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.003 · Cited by 9
Immunotherapy in inoperable stage III non-small cell lung cancer: a review
Jain, N. A., & Otterson, G. A. (2019) · Drugs in Context · doi:10.7573/dic.212578 · Cited by 9
The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
Melosky, B. L., Cheema, P. K., Juergens, R. A., Leighl, N. B., Liu, G., Wheatley‐Price, P., Sacher, A. G., Snow, S. L., Tsao, M., McLeod, D., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211056306 · Cited by 8
Clinical management of stage III non‐small cell lung cancer in India: An expert consensus statement
Batra, U., Prabhash, K., Agarwal, J. P., Darlong, L. M., Munshi, A., Penumadu, P., Thangakunam, B., & Bansal, A. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13938 · Cited by 8
Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency
Fu, W., Li, G., Lei, C., Qian, K., Zhang, S., Zhao, J., & Hu, S. (2023) · Theranostics · doi:10.7150/thno.82144 · Cited by 8
Survival outcomes of targeted and immune consolidation therapies in locally advanced unresectable lung adenocarcinoma
Wang, X., Meng, X., Cai, G., Jin, P., Bai, M., Fu, Y., Wang, Z., Guo, J., & Xiao, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111684 · Cited by 8
Phase II Trial of Combined Modality Therapy with Myeloid Growth Factor Support in Patients with Locally Advanced Non-small Cell Lung Cancer
Lilenbaum, R., Samuels, M. A., Taffaro-Neskey, M., Cusnir, M., Pizzolato, J. F., & Blaustein, A. S. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d6e141 · Cited by 8
The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer
Alexander, M., Ko, B., Lambert, R., Gadgeel, S. M., & Halmos, B. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1702526 · Cited by 9
The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues
Wang, Y., Wang, Y., Yu, J., & Meng, X. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215947 · Cited by 8
Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What Is New?
Hanna, N. H. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e442 · Cited by 8
Systemic treatment of non-small-cell lung cancer
Lal, R., Enting, D., & Kristeleit, H. (2011) · European Journal of Cancer · doi:10.1016/s0959-8049(11)70209-x · Cited by 8
Principes et traitements par chimiothérapie et radiothérapie des cancers bronchiques non à petites cellules
Cartier, L., & Fournel, P. (2009) · Encyclopédie médico-chirurgicale. Pneumologie · doi:10.1016/s1155-195x(09)39805-9 · Cited by 8
Stereotactic radiotherapy in targeted therapy treated oligo-metastatic oncogene-addicted (non-small-cell) lung cancer
Giraud, N., Abdiche, S., & Trouette, R. (2019) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2019.01.002 · Cited by 8
Treatment Intensification in Locally Advanced/Unresectable NSCLC Through Combined Modality Treatment and Precision Dose Escalation
Zeng, J., & Bowen, S. R. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.11.007 · Cited by 8
Geftinib
Gupta, A. K., & Raina, V. (2010) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.73330 · Cited by 8
Emerging Role of Targeted Therapies Combined With Radiotherapy in Inoperable Stages I to III NSCLC: A Review From the IASLC ART Subcommittee
Jones, S. B., Chan, C., Filippi, A. R., Harada, K., Louie, A. V., Lindsay, C. R., Nadal, E., Schuffenegger, P. M., Woolf, D., & Finn, C. F. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.05.004 · Cited by 10
Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997–2026)
Xie, Z., Chen, X., Gao, R., Yang, M., Han, X., Sun, Y., & Shi, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004016 · Cited by 8
Stage III: Definitive Chemoradiotherapy
Fietkau, R., & Semrau, S. (2009) · Frontiers of radiation therapy and oncology · doi:10.1159/000262467 · Cited by 7
Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer
Craene, S. D., Surmont, V. F. M., & van Meerbeeck, J. P. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328335c076 · Cited by 7
The Diagnosis and Treatment of Brain Metastases in EGFR Mutant Lung Cancer
Minchom, A. R., Yu, K. C., Bhosle, J., & O’Brien, M. (2014) · CNS Oncology · doi:10.2217/cns.14.19 · Cited by 7
Definitive Chemoradiotherapy for Non–Small Cell Lung Cancer with N2 Disease
Patel, S. A., Sanborn, R. E., & Thomas, C. R. (2008) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2008.07.003 · Cited by 7
Multimodality Therapy for NSCLC
Du, L., Waqar, S. N., & Morgensztern, D. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_7 · Cited by 7
Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy
Tazza, M., & Metro, G. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.08.130 · Cited by 7
High-Dose Radiotherapy as Neoadjuvant Treatment in Non-Small-Cell Lung Cancer
Allen, A. M., Shochat, T., Flex, D., Kramer, M. R., Zer, A., Peled, N., Dudnik, E., Fenig, E., & Saute, M. (2018) · Oncology · doi:10.1159/000487928 · Cited by 7
Current status and future directions in unresectable stage III non-small cell lung cancer
Arellano, E. A., Díaz, V. D., & Rodríguez, J. J. C. (2020) · Journal of Clinical and Translational Research · doi:10.18053/jctres.06.2020s4.006 · Cited by 7
Focus on treatment complications and optimal management: radiation oncology.
Billiet, C., Peeters, S., & Ruysscher, D. D. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.06.08 · Cited by 7
Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial
Vrankar, M., Zwitter, M., Bavcar, T., Milić, A., & Kovač, V. (2014) · Radiology and Oncology · doi:10.2478/raon-2014-0026 · Cited by 7
Thérapies ciblées et radiothérapie dans les cancers bronchiques non à petites cellules
Rivera, S., Quéro, L., Kam, S. W. H., Maylin, C., Deutsch, É., & Hennequin, C. (2011) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2011.07.234 · Cited by 8
Incorporation of Molecularly Targeted Agents in the Primary Treatment of Squamous Cell Carcinomas of the Head and Neck
Bernier, J. (2008) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2008.08.003 · Cited by 7
Refining standard practice and admitting uncertainty
Liu, S. V., & Giaccone, G. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.251 · Cited by 7
Extending Outcomes: Epidermal Growth Factor Receptor–Targeted Monoclonal Antibodies in Non–Small-Cell Lung Cancer
Joy, A. A., & Butts, C. A. (2009) · Clinical Lung Cancer · doi:10.3816/clc.2009.s.004 · Cited by 7
Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy
Milella, M., Ciuffreda, L., & Bria, E. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0507-9_2 · Cited by 7
Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis
Chang, X., Wang, Z., & Yang, L. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.910 · Cited by 7
Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine
Shen, P., & Zhong, W. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.97 · Cited by 7
A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer
Leong, S. S., Fong, K. W., Lim, W. T., Toh, C., Yap, S. P., Hee, S. W., & Tan, E. H. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.04.022 · Cited by 7
Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration
Mamdani, H. M., Jalal, S. I., & Hanna, N. H. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0364-2 · Cited by 6
Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6844 patients
Zhou, H., Zeng, C., Wang, L., Hua, X. I. E., Zhou, J., Diao, P., Yao, W., Zhao, X., & Yang, W. (2013) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20122920 · Cited by 6
Investigational agents in the management of non-small cell lung cancer
Pennell, N. A., & Mekhail, T. M. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0039-x · Cited by 6
Modern induction chemotherapy before chemoradiation for bulky locally-advanced nonsmall cell lung cancer improves survival
Ahmed, I., Ferro, A., Baby, R., Malhotra, J. D., Cohler, A., Langenfeld, J. E., Aisner, J., Zou, W., & Jabbour, S. K. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.177214 · Cited by 6
An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
Su, P., Chang, G., Hsiao, S.-H., Hsia, T., Lin, M., Lin, M., Shih, J., Yang, C., Yang, S.-H., & Chen, Y. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100292 · Cited by 6
Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study
Tang, S., Cong, X., Zheng, D., Chen, C., Liu, Z., Gao, J., Zhang, H., Zhang, Y., & Liu, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1129989 · Cited by 6
The Evolving Role of Targeted Therapy in Early-Stage and Locally Advanced Non-small Cell Lung Cancer
West, H. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0181-0 · Cited by 6
Adjuvant therapy for nonsmall cell lung cancer
Pakkala, S., & Ramalingam, S. S. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000269 · Cited by 6
Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?
Heigener, D. F., & Reck, M. (2019) · Drugs · doi:10.1007/s40265-019-01222-w · Cited by 6
Practical Value of Molecular Pathology in Stage I–III Lung Cancer: Implications for the Clinical Surgeon
Azzoli, C. G. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4704-z · Cited by 6
Clinical Aspects of Lung Cancer
Silvestri, G. A., Pastis, N. J., Tanner, N. T., & Jett, J. R. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00053-1 · Cited by 8
Self-citation
Combination strategies based on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for cancer patients
Xu, R., Shao, H., Zhu, J., Ju, Q., & Shi, H. M. (2019) · Medicine · doi:10.1097/md.0000000000014135 · Cited by 6
Impact of the ASCO 2007 Presentation of HOG Lun 01-24/USO-023 on the Prescribing Plans of American Medical Oncologists for Patients with Stage IIIB Non-small Cell Lung Cancer
Green, M. R., West, H., Socinski, M. A., Willey, J. P., Daniels, L. J., Lemke, K. E., Rafferty, G., & Iovino, L. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181adeefb · Cited by 6
Biologically Targeted Therapies Plus Chemotherapy Plus Radiotherapy in Stage III Non–Small-Cell Lung Cancer: A Case of the Icarus Syndrome?
Raben, D., & Bunn, P. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1866 · Cited by 6
Comparison of Efficacy and Safety of First-Line Treatment Options for Unresectable Stage III Non-Small Cell Lung Cancer: A Retrospective Analysis
Zhao, L., Zhao, Z., Yan, X., Wu, F., Sun, N., Guo, R., Yu, S., Hu, X., & Feng, J. (2024) · International Journal of Clinical Practice · doi:10.1155/2024/8585035 · Cited by 5
Reinventing Diagnostics for Personalized Therapy in Oncology
Banerjee, D. (2010) · Cancers · doi:10.3390/cancers2021066 · Cited by 5
Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease
Sathiyapalan, A., Baloush, Z., & Ellis, P. M. (2023) · Current Oncology · doi:10.3390/curroncol30110689 · Cited by 6
Can EGFR mutation status evolve with chemotherapy?
Kim, E. S., Stewart, D. J., & Khorana, A. A. (2013) · PubMed · doi:10.3978/j.issn.2304-3865.2012.11.09 · Cited by 5
Integrated Therapeutic Approaches in the Treatment of Locally Advanced Non-small Cell Lung Cancer
Maïo, M. D., Costanzo, R., Giordano, P., Piccirillo, M. C., Sandomenico, C., Montanino, A., Carillio, G., Muto, P., Jones, D. R., Daniele, G., et al. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113139990076 · Cited by 5
Multidisciplinary approach in stage III non-small-cell lung cancer: standard of care and open questions
Ocaña, C. V., Garrido, P., & Trueba, I. M. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0708-8 · Cited by 5
The Prognostic Significance of Lymphovascular Invasion on Biopsy Specimens in Lung Cancer Treated With Definitive Chemoradiotherapy
Massabeau, C., Filleron, T., Wakil, G., Rouquette, I., Bachaud, J., Guellec, S. L., Delisle, M., Toulas, C., Mazières, J., & Moyal, E. C. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.06.011 · Cited by 5
A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI)
Hida, N., Okamoto, H., Misumi, Y., Sato, A., Ishii, M., Kashizaki, F., Shimokawa, T., Shimizu, T., & Watanabe, K. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1871-5 · Cited by 5
Targeted therapy in nonsmall cell lung cancer
Puri, T. (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_258_17 · Cited by 5
Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer—A Secondary Analysis of the PET Plan Trial
Gkika, E., Lenz, S., Schimek‐Jasch, T., Waller, C. F., Kremp, S., Schaefer-Schuler, A., Mix, M. D., Küsters, A., Tosch, M., Hehr, T., et al. (2020) · Cancers · doi:10.3390/cancers12113359 · Cited by 5
Eventual Role of EGFR-Tyrosine Kinase Inhibitors in Early-Stage Non-Small-Cell Lung Cancer
Márquez-Medina, D., & Popat, S. (2016) · Future Oncology · doi:10.2217/fon.15.356 · Cited by 5
Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study
Hughes, B. G. M., Ahern, E. S., Lehman, M., Pratt, G. R., Dauth, M., Pritchard, W., Wockner, L. F., & Horwood, K. R. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12649 · Cited by 5
Cardiovascular Toxicity of Antitumor Drugs: Dimension of the Problem in Adult Settings
Carver, J. R., & Desai, C. J. (2010) · Wiley eBooks · doi:10.1002/9780470660379.ch5 · Cited by 5
Gefitinib Maintenance in Stage III Non–Small-Cell Lung Cancer
Stewart, D. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7625 · Cited by 5
Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non–Small-Cell Lung Cancer
Kim, Y. H., & Mishima, M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9393 · Cited by 5
Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer
Rengan, R., Redman, M. W., & Zeng, J. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.3803 · Cited by 5
The Optimization of Radiotherapy in Lung Cancer Treatment: 20 Years of Progress
Salama, J. K., Mix, M. D., Finn, C. F., Bezjak, A., & Bogart, J. A. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103578 · Cited by 5
The Slippery Slope of Broadening Treatment Eligibility and Weak End Points
West, H. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2966 · Cited by 4
Targeted therapy of non-small-cell lung carcinoma
Tiwari, D., Brodie, S. A., & Brandes, J. C. (2011) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465811404590 · Cited by 4
Predictors of Biomarkers Guiding Targeted Therapeutic Strategies in Locally Advanced Lung Cancer
Cottini, F., & Lautenschlaeger, T. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e318297216a · Cited by 4
Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR ‐tyrosine kinase inhibitors
Wang, S., Lai, C., Chen, C., Yang, S., Chang, C., Lin, C.-Y. J., Yen, Y., Tseng, Y., Su, P., Lin, C., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14237 · Cited by 4
Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis
Ciammella, P., Cozzi, S., Borghetti, P., Galaverni, M., Nardone, V., Ruggieri, M. P., Sepulcri, M., Scotti, V., Bruni, A., Zanelli, F., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1325249 · Cited by 4
Understanding lung cancer molecular subtypes
Pender, A., & Popat, S. (2014) · Clinical Practice · doi:10.2217/cpr.14.39 · Cited by 4
Adjuvant and Neoadjuvant Chemotherapy for Early-Stage Nonsmall Cell Lung Cancer
Scagliotti, G. V., & Vokes, E. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00051-2 · Cited by 4
Targeting minimal residual disease after surgery with molecular targeted therapy: the real path to a cure?
Masago, K., Fujita, S., & Yatabe, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.04.155 · Cited by 4

Authors: Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R.
Affiliations: Sunnybrook Health Science Centre (CA)
ORCID: Kelly, Karen
Albain, Kathy S.
Ung, Yee C.
Gandara, David R.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2008-05-20
Volume: 26
Issue: 15
Pages: 2450-2456
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2007.14.4824
OpenAlex: W2153865661
Cited by: 573
References: 31
Citations by year: 2026: 5 · 2025: 6 · 2024: 11 · 2023: 18 · 2022: 11 · 2021: 31 · 2020: 24 · 2019: 22 · 2018: 39 · 2017: 24 · 2016: 41 · 2015: 40 · 2014: 44 · 2013: 57 · 2012: 41
FWCI: 48.16
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Sanofi
National Institutes of Health (2u10ca038926-25, 5r01ca037663-18)
National Cancer Institute (CA35192, U10CA004919, CA 35176, CA-11083, CA52654, CA-45377, U10CA035261, CA35281, CA 74811, CA-35261, CA-46282, CA 20319, CA-32102, U10CA074647, CA 45450, CA35119, CA 42777, U10CA045377, CA04919, U10CA058882, U10CA074811, U10CA014028, U10CA045560, U10CA063848, U10CA035178, CA 74647, U10CA045808, CA35128, CA46368, CA46441, CA 63845, U10CA046368, CA45808, CA 45461, CA67575, U10CA035090, CA 14028, U10CA020319, U10CA086780, U10CA011083, CA-58882, CA35178, CA-45807, U10CA013612, CA 37663, U10CA035119, U10CA063850, CA35431, U10CA032102, U10CA046282, U10CA045461, U10CA052654, U10CA045450, U10CA042777, U10CA035281, CA 13612, U10CA063845, U10CA045807, U10CA063844, U10CA035431, CA-35262, U10CA035192, CA 38926, U10CA035262, CA63844, CA86780, U10CA035176, U10CA035128, CA-63850, CA-63848, CA45560, U10CA067575, CA-35090, U10CA046441)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: gefitinib, maintenance therapy, non-small cell lung cancer, stage III NSCLC, inoperable lung cancer, concurrent chemoradiotherapy, cisplatin, etoposide, thoracic radiotherapy, EGFR tyrosine kinase inhibitors, survival, toxic death
MeSH terms: Docetaxel, Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cisplatin, Combined Modality Therapy, Etoposide, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Quinazolines, Remission Induction, Survival Rate, Maximum Tolerated Dose, Taxoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks